Document is current
Any future updates will be listed below
-
Authors
Hardtstock, Fränce https://orcid.org/0000-0003-4698-1628
Kocaata, Zeki
Wilke, Thomas
Dittmar, Axel
Ghiani, Marco
Belozeroff, Vasily
Harrison, David J.
Maywald, Ulf
Tesch, Hans
-
Funding
Funding for this research was provided by:
Amgen
- License Information
-
More Information
Article History
Received: 26 August 2020
Accepted: 16 November 2020
First Online: 18 January 2021
Compliance with ethical standards
:
: Vasily Belozeroff and David J. Harrison are employees and shareholders of Amgen. Fränce Hardtstock and Zeki Kocaata have no conflict of interest to declare. Thomas Wilke has acted as a consultant for Boehringer Ingelheim Pharma, Bayer Health Care, GSK, Novartis, Sanofi-Aventis, Bristol Myers Squibb, Pfizer and other pharmaceutical companies. Marco Ghiani and Axel Dittmar are employees of IPAM and do not have any conflict of interest to declare. Ulf Maywald works for one of the insurance funds that provided the study data (AOK PLUS). Hans Tesch, who is working as a physician in the field of oncology, supported the study as a scientific advisor and received honoraria from Amgen, Novartis, Pfizer and other pharmaceutical companies.
: Due to the non-interventional, retrospective nature of this study and because our analysis involved an anonymized dataset, neither ethical review nor informed consent of the patients was required. However, the study protocol was reviewed and approved by the sickness fund (AOK PLUS), before access to the data was granted.
